A Phase 1 interventional study of ABBV-950 and BOTOX in Upper Limb Spasticity, sponsored by AbbVie. Terminated at 9 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing botulinum toxin type A in Muscle Spasticity — 4 open to participants now, 4 under way, 1 of them phase 3. botulinum toxin type A · Muscle Spasticity.
Among the 58 studies testing botulinum toxin type A in Muscle Spasticity, this one is the 56th largest by enrollment, is the only one that started in 2024, is one of 4 in phase 1, and was the 54th registered.
622 studies on the registry are indexed under Muscle Spasticity; 128 are open to participants now.
Browse Muscle Spasticity studies →4 of the 58 studies testing botulinum toxin type A in Muscle Spasticity are open now, in 4 countries. Recruiting first, the newest first:
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 18–80
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
Technical University of Bern · Sites in Switzerland, United Kingdom
Ages 18+
Universita di Verona
Ages 2–17
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2024.
This study's enrollment of 1 is below the median of 36 across 473 interventional studies indexed under Muscle Spasticity.
Median enrollment 62 across the 58 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 58 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
19 studies in Muscle Spasticity by AbbVie: none open now, none under way, none of them phase 3. Of 17 finished, 12 (71%) have results posted.
Among the 19 studies in Muscle Spasticity by AbbVie, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1, and was the 18th registered.
AbbVie’s Muscle Spasticity studies by the year they started, since 2003.
1 of the studies testing botulinum toxin type A in Muscle Spasticity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06811142Instituto Mexicano del Seguro SocialEarly Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 58 studies testing botulinum toxin type A in Muscle Spasticity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 19 in Muscle Spasticity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. Common causes of spasticity include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke. This study will assess how safe and effective ABBV-950 is in treating upper limb spasticity in adult post-stroke participants. Adverse events and change in symptoms will be assessed.
ABBV-950 in an investigational drug being developed for treating spasticity. This study is conducted in 2 parts. In Part 1, participants are assigned to receive different doses of ABBV-950 or placebo. There is 1 in 4 chance that participants will be assigned to receive placebo. In Part 2, participants will be randomly assigned to receive BOTOX, ABBV-950, or placebo. There is 1 in 5 chance for participants to receive placebo. Approximately 297 adult post-stroke participants with upper limb spasticity will be enrolled at approximately 50 sites in the United States.
In Part 1, participants will receive intramuscular (IM) injections of ABBV-950 or placebo on Day 1. In Part 2, participants will receive IM injections of BOTOX, ABBV-950, or placebo on Day 1. All participants will be followed for 24 weeks.
There may be higher treatment burden for participants in this trial compared to the standard of care. Participants will attend regular clinic visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ABBV-Dose A on Day 1.
Biological: ABBV-950
Participants will receive placebo for ABBV-950 on Day 1.
Drug: Placebo for ABBV-950
Participants will receive ABBV-950 Dose B on Day 1.
Biological: ABBV-950
Participants will receive placebo for ABBV-950 on Day 1.
Drug: Placebo for ABBV-950
Participants will receive ABBV-950 Dose C on Day 1.
Biological: ABBV-950
Participants will receive placebo for ABBV-950 on Day 1.
Drug: Placebo for ABBV-950
Participants will receive BOTOX Dose A on Day 1.
Biological: BOTOX
Participants will receive ABBV-950 Dose A on Day 1.
Biological: ABBV-950
Participants will receive ABBV-950 Dose B on Day 1.
Biological: ABBV-950
Participants will receive ABBV-950 Dose C on Day 1.
Biological: ABBV-950
Participants will receive placebo for ABBV-950 on Day 1.
Drug: Placebo for ABBV-950
Change From Baseline in Wrist Modified Ashworth Scale-Bohannon (MAS-B)
MAS-B measures muscle tone based on grading the resistance encountered in a specific muscle group by means of passively moving a limb through its range of motion at a study-specified velocity. Score ranges from 0 (No increase in muscle tone) through 4 (Affected part(s) rigid in flexion or extension).
Time frame: Up to Week 6
Number of Participants Experiencing Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to Week 24
Change in Clinician Global Impression of Change (CGI-C) Score
CGI-C is a 9-point rating scale used to measure the clinician's impression of overall treatment response since the first dose of study intervention. CGI-C scores range from -4 = very marked worsening to +4 = very marked improvement.
Time frame: Up to Week 6
Change in Clinician Global Impression of Severity (CGI-S) Score
CGI-S is a 5-point rating scale used to measure the clinician's or trained personnel's impression of the current severity of the participant's upper limb spasticity. Scores range from 0 = no spasticity to 4 = very severe.
Time frame: Up to Week 6
Percentage of Participants Achieving Wrist MAS-B Responder Status
MAS-B measures muscle tone based on grading the resistance encountered in a specific muscle group by means of passively moving a limb through its range of motion at a study-specified velocity. Score ranges from 0 (No increase in muscle tone) through 4 (Affected part(s) rigid in flexion or extension). Responder is defined as participant with \>= 1 grade improvement from baseline.
Time frame: Up to Week 6
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Jan 2024 to primary completion in Jun 2024, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A